Compare CPB & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPB | CNTA |
|---|---|---|
| Founded | 1869 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 6.1B |
| IPO Year | 1994 | 2021 |
| Metric | CPB | CNTA |
|---|---|---|
| Price | $22.88 | $39.69 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 18 | 9 |
| Target Price | $26.06 | ★ $43.17 |
| AVG Volume (30 Days) | ★ 8.2M | 1.2M |
| Earning Date | 06-01-2026 | 05-13-2026 |
| Dividend Yield | ★ 7.63% | N/A |
| EPS Growth | 6.35 | ★ 29.13 |
| EPS | ★ 1.55 | N/A |
| Revenue | ★ $10,253,000,000.00 | $15,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.11 | N/A |
| P/E Ratio | $14.28 | ★ N/A |
| Revenue Growth | ★ 6.40 | N/A |
| 52 Week Low | $19.56 | $11.77 |
| 52 Week High | $34.18 | $40.26 |
| Indicator | CPB | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 74.22 | 63.87 |
| Support Level | $19.78 | $39.36 |
| Resistance Level | $31.86 | $39.90 |
| Average True Range (ATR) | 0.77 | 0.15 |
| MACD | 0.26 | -0.13 |
| Stochastic Oscillator | 95.79 | 45.57 |
Over the past 150-plus years, Campbell's has evolved into a leading domestic packaged food manufacturer, with a portfolio that extends beyond its iconic red-and-white labeled canned soup. In fiscal 2025 (July year-end), snacks accounted for 43% of its revenue, followed by soup (27%), other simple meals (23%), and beverages (7%). Beyond its namesake, its brands include Pepperidge Farm, Goldfish, Snyder's of Hanover, Swanson, Pacific Foods, Prego, Pace, V8, and, most recently, Rao's (a deal that closed in 2024). Around 90% of its revenue results from the US and the remainder from Canada and Latin America.
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.